TrialBMC cancer2017

A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer.

Xin Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.